Novo Nordisk faces mixed analyst ratings and growth concerns

Financial analysts have issued conflicting outlooks for Novo Nordisk. Deutsche Bank downgraded the company from ‘hold’ to ‘sell’, lowering its price target from 290 to 265 DKK. This pessimism stems from concerns regarding stagnant revenue through 2027 and potential profit declines driven by lower US prices, increased discounts, and competition from Eli Lilly and cheaper semaglutide alternatives.

In contrast, Erste Group Bank increased its FY2026 earnings per share (EPS) estimate for Novo Nordisk to $3.46, up from a previous estimate of $3.27. While Deutsche Bank warns of a lack of convincing growth, other institutions maintain varied stances, with the current consensus rating for the stock sitting at ‘hold’.